Genetic Heterogeneity, Therapeutic Hurdle Confronting Sorafenib and Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.

Atwa, Sara M; Odenthal, Margarete; El Tayebi, Hend M

Atwa, Sara M; Odenthal, Margarete; El Tayebi, Hend M.

Afiliación

Atwa SM; Pharmaceutical Biology Department, German University in Cairo, Cairo 11865, Egypt.
Odenthal M; Molecular Pharmacology Research Group, Department of Pharmacology and Toxicology, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo 11835, Egypt.
El Tayebi HM; Institute for Pathology, University Hospital Cologne, 50924 Cologne, Germany.

Cancers (Basel) ; 13(17)2021 08 27.

Article en En | MEDLINE | ID: mdl-34503153

Palabras clave

ANGPT-2; cell death; drug resistance; drug transport; eNOS; genetic variants; immune checkpoint; liver cancer; signaling pathways; sorafenib

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2021 Tipo del documento: Article País de afiliación: Egipto Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google